R. Plummer
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
Plummer, R.; Wilson, R.H.; Calvert, H.; Boddy, A.V.; Griffin, M.; Sludden, J.; Tilby, M.J.; Eatock, M.; Pearson, D.G.; Ottley, C.J.; Matsumura, Y.; Kataoka, K.; Nishiya, T.
Authors
R.H. Wilson
H. Calvert
A.V. Boddy
M. Griffin
J. Sludden
M.J. Tilby
M. Eatock
D.G. Pearson
Dr Christopher Ottley c.j.ottley@durham.ac.uk
Chief Experimental Officer - Geochemistry
Y. Matsumura
K. Kataoka
T. Nishiya
Abstract
Background: On the basis of preclinical studies of NC-6004, a cisplatin-incorporated micellar formulation, we hypothesised that NC-6004 could show lower toxicity than cisplatin and show greater anti-tumour activity in phase I study. Methods: A total of 17 patients were recruited in a range of advanced solid tumour types. NC-6004 was administered intravenously (i.v.) every 3 weeks. The dose escalation started at 10mgm−2 and was increased up to 120mgm−2 according to the accelerated titration method and modified Fibonacci method. Results: One dose-limiting toxicity (DLT) occurred in a patient who was given 90mgm−2 of NC-6004, otherwise any significant cisplatin-related toxicity was not observed or generally mild toxicity was observed. Despite the implementation of post-hydration and pre-medication regimen, renal impairment and hypersensitivity reactions still developed at 120mgm−2, which led to the conclusion that the maximum tolerated dose was 120mgm−2, and the recommended dose was 90mgm−2, although DLT was not defined as per protocol. Stable disease was observed in seven patients. The maximum concentration and area under the concentration–time curve of ultrafilterable platinum at 120mgm−2 NC-6004 were 34-fold smaller and 8.5-fold larger, respectively, than those for cisplatin. Conclusion: The delayed and sustained release of cisplatin after i.v. administration contributes to the low toxicity of NC-6004.
Citation
Plummer, R., Wilson, R., Calvert, H., Boddy, A., Griffin, M., Sludden, J., …Nishiya, T. (2011). A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. British Journal of Cancer, 104(4), 593-598. https://doi.org/10.1038/bjc.2011.6
Journal Article Type | Article |
---|---|
Publication Date | Feb 1, 2011 |
Deposit Date | Jan 18, 2012 |
Journal | British Journal of Cancer |
Print ISSN | 0007-0920 |
Electronic ISSN | 1532-1827 |
Publisher | Springer Nature |
Peer Reviewed | Peer Reviewed |
Volume | 104 |
Issue | 4 |
Pages | 593-598 |
DOI | https://doi.org/10.1038/bjc.2011.6 |
Keywords | Cisplatin, DDS, EPR effect, NC-6004, Phase I study, Polymer micelle. |
Public URL | https://durham-repository.worktribe.com/output/1522175 |
You might also like
The effect of magnetic resonance imaging on mercury release from dental amalgam at 3T and 7T
(2022)
Journal Article